Ascendia

  MARKET NEWS

TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint0Resistant Metastatic Melanoma Phase 1 Trial
Rigel Pharmaceuticals & MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML & Other Cancers
Incannex Provides Update on Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting With FDA for Rosacea Treatment
Vetter Joins Science Based Targets Initiative (SBTi)
Recipharm Announces Collaboration With Oz-UK to Accelerate the Development of Low Global Warming Potential pMDIs Utilizing HFA-152a Propellant

  FEATURED EDITORIAL

  COMPANY PROFILE


Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. Over the past 20 years, Abzena has helped hundreds of customers ranging from emerging biotechs to the top large pharmaceutical firms deliver on their research and development objectives and achieve their regulatory and clinical milestones. With extensive scientific knowledge and technical expertise, our global teams provide customers with comprehensive support that minimizes risks and moves new medicines forward faster- with greater success. Click here for more.

  EXCLUSIVE ONLINE CONTENT

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen & Ultevursen Ophthalmic Assets

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen & Ultevursen Ophthalmic Assets

Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double-digit royalties based on commercial sales in the US and EU….

IMIDomics & Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research & Development

IMIDomics & Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research & Development

IMIDomics recently announced it is expanding its strategic collaboration with Bristol Myers Squibb that extends the existing relationship between the two companies, advancing their shared commitment to….

ONK Therapeutics & NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies & FLEX-NK Bispecific Antibodies

ONK Therapeutics & NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies & FLEX-NK Bispecific Antibodies

ONK Therapeutics and NAYA Biosciences Inc. announced they have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally engineered natural….

Colorcon Unveils Corelease - A Unified Brand for Novel Controlled-Release Formulated Systems

Colorcon Unveils Corelease - A Unified Brand for Novel Controlled-Release Formulated Systems

Ready formulated systems approach simplifies the development and manufacturing for controlled release…..

  WHITEPAPERS & WEBINARS

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..

WEBINAR - Enabling Upstream Intensified Bioprocessing

WEBINAR - Enabling Upstream Intensified Bioprocessing

Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 20 – ODT/Fast Dissolve
December 27 – Lyophilization Manufacturing